Economics

0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

L
LabcorpNC - Burlington
2 programs
Informative letterN/A1 trial
Patient Consequences LetterN/A1 trial
Active Trials
NCT02345434Completed1,525Est. Aug 2015
NCT03202745Withdrawn0Est. Jan 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
LabcorpPatient Consequences Letter
LabcorpInformative letter

Clinical Trials (2)

Total enrollment: 1,525 patients across 2 trials

NCT03202745LabcorpPatient Consequences Letter

The Effect of Informative Letters on the Prescription and Receipt of Opioids

Start: Jan 2017Est. completion: Jan 20190
N/AWithdrawn
NCT02345434LabcorpInformative letter

The Effect of Informative Letters on the Prescription and Receipt of Schedule II Controlled Substances

Start: Aug 2014Est. completion: Aug 20151,525 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space